Skip to main
ARDT

ARDT Stock Forecast & Price Target

ARDT Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 27%
Buy 36%
Hold 27%
Sell 9%
Strong Sell 0%

Bulls say

Ardent Health Inc. demonstrated a significant financial performance with EBITDA increasing by 46% year-over-year to $143 million, accompanied by an improved margin of 9.1%, marking a 240 basis point rise. The company also experienced a 5.8% year-over-year growth in inpatient admissions, outperforming the peer average of 1.7%, indicating strong demand for its services. Despite challenges with professional fees, management anticipates that ongoing investment in technologies and services, along with an expected uptick in capital expenditures, will contribute positively to future growth.

Bears say

Ardent Health Inc's financial outlook appears negative due to a combination of disappointing EBITDA performance and challenges in revenue management. The company experienced a 2% miss on EBITDA expectations, exacerbated by a shift in revenue recognition related to its transition to a new revenue cycle management platform, which has resulted in conservative assumptions regarding accounts receivable collectability. Additionally, ongoing issues with increased claims denials and professional fee pressures are projected to lead to minimal or negative EBITDA growth in 2026, significantly lowering EBITDA-NCI estimates for both 2025 and 2026.

ARDT has been analyzed by 11 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 36% recommend Buy, 27% suggest Holding, 9% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ardent Health Partners LLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ardent Health Partners LLC (ARDT) Forecast

Analysts have given ARDT a Buy based on their latest research and market trends.

According to 11 analysts, ARDT has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ardent Health Partners LLC (ARDT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.